Zelmac Pooled Study Results May Not Be Reflective Of Efficacy - FDA
Executive Summary
Pooling of efficacy data across three trials for Novartis' irritable bowel syndrome therapy Zelmac may not be appropriate because of mixed outcomes among the trials, FDA indicated in briefing documents prepared for the Gastrointestinal Drugs Advisory Committee meeting June 26.
You may also be interested in...
Latest Zelmac Trial Focuses On 12 Mg Dose In Women; Drug Is "Approvable"
Novartis' latest trial for the irritable bowel syndrome agent Zelmac focuses on a 12 mg daily dosing regimen in 1,500 females, with results to be submitted to FDA by the end of the year.
Latest Zelmac Trial Focuses On 12 Mg Dose In Women; Drug Is "Approvable"
Novartis' latest trial for the irritable bowel syndrome agent Zelmac focuses on a 12 mg daily dosing regimen in 1,500 females, with results to be submitted to FDA by the end of the year.
Novartis Zelmac Dosing Instructions Among Remaining Issues In FDA Review
FDA will have to decide between a high dose or titrated regimen for Novartis' irritable bowel syndrome therapy Zelmac following a review by the Gastrointestinal Drugs Advisory Committee.